Zai Lab Limited (NASDAQ:ZLAB) Stock Holdings Lifted by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in Zai Lab Limited (NASDAQ:ZLAB) by 26.4% during the third quarter, HoldingsChannel.com reports. The fund owned 43,626 shares of the company’s stock after buying an additional 9,107 shares during the period. Geode Capital Management LLC’s holdings in Zai Lab were worth $1,053,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Janus Henderson Group PLC raised its holdings in Zai Lab by 34.2% during the 3rd quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company’s stock worth $211,488,000 after buying an additional 2,232,507 shares during the period. Wellington Management Group LLP boosted its stake in Zai Lab by 18.4% in the 3rd quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company’s stock worth $203,660,000 after purchasing an additional 1,312,115 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in Zai Lab by 26.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company’s stock worth $14,584,000 after purchasing an additional 125,532 shares in the last quarter. Bamco Inc. NY raised its stake in Zai Lab by 6.4% during the 3rd quarter. Bamco Inc. NY now owns 1,906,520 shares of the company’s stock valued at $46,023,000 after purchasing an additional 113,869 shares during the period. Finally, Algert Global LLC acquired a new stake in shares of Zai Lab in the third quarter worth $1,666,000. 41.65% of the stock is owned by institutional investors and hedge funds.

Zai Lab Price Performance

ZLAB stock opened at $24.30 on Friday. The company has a 50-day moving average of $27.59 and a two-hundred day moving average of $23.22. The stock has a market capitalization of $2.66 billion, a price-to-earnings ratio of -8.77 and a beta of 1.00. Zai Lab Limited has a 52-week low of $13.48 and a 52-week high of $36.60.

Wall Street Analyst Weigh In

A number of brokerages have commented on ZLAB. JPMorgan Chase & Co. raised their price objective on Zai Lab from $38.00 to $44.00 and gave the stock an “overweight” rating in a research report on Monday, October 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a research note on Friday, October 25th.

Insider Buying and Selling at Zai Lab

In other news, insider Rafael Amado sold 7,583 shares of Zai Lab stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total transaction of $199,281.24. Following the sale, the insider now directly owns 33,834 shares in the company, valued at approximately $889,157.52. The trade was a 18.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 13.88% of the company’s stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.